Atika Capital Management LLC Krystal Biotech, Inc. Transaction History

Atika Capital Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$48.93 - $73.47 $1.47 Million - $2.2 Million	30,000 New	30,000 $1.97 Million
Q1 2020 May 14, 2020	SELL	$35.02 - $65.64 $2.04 Million - $3.83 Million	-58,319 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $2.02 Million - $2.99 Million	58,319 New	58,319 $2.03 Million

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.